Restart Life Sciences Corp.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Restart Life Sciences Corp. (CSE: HEAL) is a Canadian life sciences company focused on developing and commercializing innovative wellness solutions that address health challenges including cognitive health, mental clarity, autism spectrum disorders, and brain health; its core products and services encompass natural remedies tailored for individuals on the autism spectrum, health-related foods and functional snacks such as those under the Brain Balls brand via joint venture, proprietary psilocybin-based therapies for fragile X syndrome with orphan drug designations from the FDA and EMA, and nutritional innovations promoting mind and body wellness. The company, formerly known as Nova Mentis Life Science Corp., changed its name in November 2024 and was incorporated in 2004 with headquarters in Vancouver, British Columbia; it operates primarily in Canada while pursuing global expansion through partnerships and targets consumers in the fast-growing health and wellness sector, including underserved markets for neuroinflammatory and cognitive disorders. Recent developments include a December 2024 joint venture with Brain Balls Inc. for health-focused snacks targeting cognitive performance, a February 2025 strategic production partnership with a leading Canadian co-packer for manufacturing and distribution of Brain Balls and related lines, a March 2025 trademark licensing agreement to bolster intellectual property for brand development, cancellation of a planned LIFE financing in August 2025 to enhance flexibility for new partnerships and joint ventures, and a November 2025 private placement financing to support health food trials, potential acquisitions, and working capital.
Company News
Restart Life Advances Licensed Intellectual Property Portfolio Toward Commercial Launch
Restart Life Sciences Launches HC Protein+ Products Online and Advances AI-Driven E-Commerce Strategy
Holy Crap Foods to Exhibit at CHFA NOW Toronto, Debuting New Protein SKUs and Interactive AI Photo Experience
Restart Life Sciences Reports Second Quarter 2026 Results Highlighted by 146% Sequential Revenue Growth
Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
Restart Life Sciences Announces Production Launch of New Holy Crap Protein Line
Restart Life Sciences Announces Strategic Focus on Targeted M&A Expansion in Health and CPG Sectors
Restart Life Sciences Details U.S. E-Commerce Launch, AI Platform, and Three-Phase Expansion Strategy for Holy Crap Foods
Restart Life Sciences Leverages University of Manitoba RCFTR Collaboration for Pre-Production Transition of New Protein Frameworks
Restart Life Sciences Details Next-Generation Product Pipeline and Segment Expansion for Holy Crap
Restart Life Sciences Reports Record-Breaking June Revenue for Holy Crap Foods as Amazon Canada Sales Surge YoY
Restart Life Advances AI-Driven E-Commerce Strategy to Scale Online Sales Growth for Holy Crap Foods
Restart Life Subsidiary Holy Crap Foods Marks New International Expansion Milestone with Bahamas On-Demand App Launch
Restart Life Sciences Appoints Inez Ho as Chief Financial Officer
Restart Life Sciences Closes Dedicated Purchase Order Financing Private Placement; CEO Subscribes for 50% of Offering
Restart Life Sciences Advances New Product Relaunch Utilizing Acquired Intellectual Property Portfolio
Restart Life Sciences Leverages Amazon Logistics for Strategic Entry of Holy Crap Foods into U.S. Market
Restart Life Sciences Announces Dedicated Purchase Order Financing Through Private Placement Offering
Restart Life Sciences Strengthens Operational Infrastructure to Scale "Better-for-You" Portfolio
Restart Life Sciences Appoints Capital Markets Veteran Lindsay Hamelin to Board of Directors